MONTPELLIER CANCER CENTER Post-doctoral position in cancer
Transcription
MONTPELLIER CANCER CENTER Post-doctoral position in cancer
MONTPELLIER CANCER CENTER Post-doctoral position in cancer biology to study metabolic reprogramming during melanoma progression The Le Cam's laboratory in Montpellier Cancer Center (IRCM, www.ircm.fr) is looking for a postdoctoral research fellow to develop a project on metabolic reprogramming of melanoma cells and its role in tumor invasiveness. The project will focus on the role of important components of the p53 pathway in the metabolic reprogramming of melanoma cells, using genetically engineered mouse models and human melanoma samples. The candidate will also study tumor heterogeneity from the metabolic point of view, using cutting edge technologies including Mass-Spectrometry tissue imaging techniques, single cell tracing and analyses, tissue imaging and 3D reconstruction approaches. As a start, the successful candidate will be appointed with a 2 years felllowship from the Labex Epigenmed consortium (www.epigenmed.fr). Preferred Qualifications: Some prior experience in mouse genetics and/or mass spectrometry analyses are preferred For more information about this position and the project, please contact [email protected] Research Summary of the laboratory Our team is interested in molecular circuitries implicated in cellular senescence and stem cell function, and how deregulation of these biological processes affects organismal aging and tumorigenesis. Our project aims at characterizing new regulatory mechanisms of the p53 pathway, including those implicating the multifunctional protein E4F1 and the MDM2 oncoprotein. Both E4F1 and Mdm2 are E3 ligases that regulate p53 at the post-translational level. In the past years, we also identified atypical functions of those important regulators of the p53 pathway and found that they regulate various metabolic pathways. Using genetically engineered mouse models and metabolomic approaches, we are characterizing the impact of those complex metabolic networks in stem cell maintenance and normal tissue homeostasis. In collaboration with clinicians and pathologists, we also investigate the relevance of these new regulatory mechanisms of the p53 pathway to human tumorigenesis, with a particular interest in melanoma and liposarcoma. Bibliography from the host laboratory: • Rodier G.*, et al. (2015). The transcription factor E4F1 coordinates CHK1-dependent checkpoint and mitochondrial functions. Cell Rep. Apr 14;11(2):220-33. • Hatchi E. et al. (2011) E4F1 deficiency results in oxidative stress-mediated cell death of leukemic cells. J. Exp. Med. Jul 4;208(7):1403-17. • Lacroix M. et al. (2010). Transcription factor E4F1 is essential for epidermal stem cell maintenance and skin homeostasis. Proc Natl Acad Sci U S A. Dec 7; 107(49): 21076-81 • Le Cam L. et al. (2006). E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. Nov17;127(4):775-88. L LauLauren Institut de Recherche en Cancérologie, INSERM U1194, 208 rue des apothicaires 34298 Montpellier Cedex 5 – France www.ircm.fr